169 related articles for article (PubMed ID: 15879768)
1. Renal medullary carcinoma and ABL gene amplification.
Simpson L; He X; Pins M; Huang X; Campbell SC; Yang XJ; Perlman EJ; Bergan RC
J Urol; 2005 Jun; 173(6):1883-8. PubMed ID: 15879768
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling of renal medullary carcinoma: potential clinical relevance.
Yang XJ; Sugimura J; Tretiakova MS; Furge K; Zagaja G; Sokoloff M; Pins M; Bergan R; Grignon DJ; Stadler WM; Vogelzang NJ; Teh BT
Cancer; 2004 Mar; 100(5):976-85. PubMed ID: 14983493
[TBL] [Abstract][Full Text] [Related]
3. Cytologic features of renal medullary carcinoma.
Assad L; Resetkova E; Oliveira VL; Sun W; Stewart JM; Katz RL; Caraway NP
Cancer; 2005 Feb; 105(1):28-34. PubMed ID: 15593260
[TBL] [Abstract][Full Text] [Related]
4. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.
Schaeffer EM; Guzzo TJ; Furge KA; Netto G; Westphal M; Dykema K; Yang X; Zhou M; Teh BT; Pavlovich CP
BJU Int; 2010 Jul; 106(1):62-5. PubMed ID: 20002663
[TBL] [Abstract][Full Text] [Related]
5. [Clinical characteristics and outcomes of 59 patients with acute lymphoblastic leukemia positive for BCR/ABL].
Liu Z; Liu XL; Du QF; Xu N; Zhong M; Song LL; Yi ZS; Liu QF; Meng FY; Zhou SY
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Mar; 29(3):512-5. PubMed ID: 19304540
[TBL] [Abstract][Full Text] [Related]
6. Renal medullary carcinoma in a white adolescent with sickle cell trait.
Daher P; Bourgi A; Riachy E; Khoury A; Rehayem C; Sader-Ghorra C
J Pediatr Hematol Oncol; 2014 Jul; 36(5):e285-9. PubMed ID: 24517963
[TBL] [Abstract][Full Text] [Related]
7. Prolonged survival of a patient with sickle cell trait and metastatic renal medullary carcinoma.
Pirich LM; Chou P; Walterhouse DO
J Pediatr Hematol Oncol; 1999; 21(1):67-9. PubMed ID: 10029817
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
Gadzicki D; von Neuhoff N; Steinemann D; Just M; Büsche G; Kreipe H; Wilkens L; Schlegelberger B
Cancer Genet Cytogenet; 2005 Jun; 159(2):164-7. PubMed ID: 15899391
[TBL] [Abstract][Full Text] [Related]
9. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
[TBL] [Abstract][Full Text] [Related]
10. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
11. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Gorre ME; Mohammed M; Ellwood K; Hsu N; Paquette R; Rao PN; Sawyers CL
Science; 2001 Aug; 293(5531):876-80. PubMed ID: 11423618
[TBL] [Abstract][Full Text] [Related]
12. ALK rearrangement in sickle cell trait-associated renal medullary carcinoma.
Mariño-Enríquez A; Ou WB; Weldon CB; Fletcher JA; Pérez-Atayde AR
Genes Chromosomes Cancer; 2011 Mar; 50(3):146-53. PubMed ID: 21213368
[TBL] [Abstract][Full Text] [Related]
13. Deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia.
Lee YK; Kim YR; Min HC; Oh BR; Kim TY; Kim YS; Cho HI; Kim HC; Lee YS; Lee DS
Cancer Genet Cytogenet; 2006 Apr; 166(1):65-73. PubMed ID: 16616113
[TBL] [Abstract][Full Text] [Related]
14. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.
Griesinger F; Hennig H; Hillmer F; Podleschny M; Steffens R; Pies A; Wörmann B; Haase D; Bohlander SK
Genes Chromosomes Cancer; 2005 Nov; 44(3):329-33. PubMed ID: 16001431
[TBL] [Abstract][Full Text] [Related]
15. Renal medullary carcinoma: prolonged remission with chemotherapy, immunohistochemical characterisation and evidence of bcr/abl rearrangement.
Stahlschmidt J; Cullinane C; Roberts P; Picton SV
Med Pediatr Oncol; 1999 Dec; 33(6):551-7. PubMed ID: 10573578
[TBL] [Abstract][Full Text] [Related]
16. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
17. [The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
Miyanishi S; Umeki K; Hayashi T; Fukutsuka K; Okumura A; Kishimori C
Rinsho Byori; 2003 Oct; 51(10):1023-9. PubMed ID: 14653203
[TBL] [Abstract][Full Text] [Related]
18. Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ all treated with imatinib containing regimen: preliminary report of two cases.
Miglino M; Varaldo R; Colombo N; Grasso R; Clavio M; Garuti A; Aquino S; Albarello A; Sessarego M; Gobbi M
J Exp Clin Cancer Res; 2006 Sep; 25(3):321-4. PubMed ID: 17167971
[TBL] [Abstract][Full Text] [Related]
19. Interpretation of submicroscopic deletions of the BCR or ABL gene should not depend on extra signal-FISH: problems in interpretation of submicroscopic deletion of the BCR or ABL gene with extra signal-FISH.
Kim YR; Cho HI; Yoon SS; Park S; Kim BK; Lee YK; Chun H; Kim HC; Lee DS
Genes Chromosomes Cancer; 2005 May; 43(1):37-44. PubMed ID: 15723338
[TBL] [Abstract][Full Text] [Related]
20. Renal medullary carcinoma and its association with sickle cell trait: a case report and literature review.
Holland P; Merrimen J; Pringle C; Wood LA
Curr Oncol; 2020 Feb; 27(1):e53-e56. PubMed ID: 32218668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
